Benzinga | Oct 30, 2020 09:00AM EDT

Credit Suisse Maintains Outperform on Amedisys, Raises Price Target to $280

Credit Suisse analyst A.J. Rice maintains Amedisys (NASDAQ:AMED) with a Outperform and raises the price target from $246 to $280.